- Home
- UAN vs SVRA Comparison
UAN vs SVRA Comparison
Compare UAN & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAN | SVRA |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2008 | 2009 |
Fundamental Metrics
Financial Performance| Metric | UAN | SVRA |
|---|---|---|
| Price | $124.08 | $5.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.94 |
| AVG Volume (30 Days) | 15.0K | ★ 1.5M |
| Earning Date | 10-28-2026 | 11-11-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | ★ 61.98 | N/A |
| EPS | ★ 12.06 | N/A |
| Revenue | ★ $606,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3,963.52 |
| P/E Ratio | $10.34 | ★ N/A |
| Revenue Growth | ★ 15.36 | N/A |
| 52 Week Low | $89.20 | $3.34 |
| 52 Week High | $139.50 | $7.01 |
Technical Indicators
Market Signals| Indicator | UAN | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 45.29 |
| Support Level | $121.55 | $5.16 |
| Resistance Level | $138.77 | $5.49 |
| Average True Range (ATR) | 3.39 | 0.22 |
| MACD | -1.28 | -0.01 |
| Stochastic Oscillator | 18.19 | 45.11 |
Price Performance
Historical ComparisonAbout UAN CVR Partners LP
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).